ibandronic acid has been researched along with Disease Models, Animal in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 11 (68.75) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akagawa, M; Imai, Y; Kasukawa, Y; Kawatani, M; Miyakoshi, N; Nagahata, I; Nagasawa, H; Ono, Y; Sato, C; Shimada, Y; Tsuchie, H; Yuasa, Y | 1 |
| Shiraishi, A | 1 |
| Aya-ay, J; Browne, R; Garces, A; Kamiya, N; Kim, HK; Vandermeer, JS | 1 |
| Iwata, K; Kaji, Y; Komatsubara, S; Manabe, T; Mashiba, T; Mori, S; Yamamoto, T | 1 |
| Biskobing, DM; Downs, R; Novy, AM | 1 |
| Hiraga, T; Michigami, T; Mundy, GR; Niewolna, M; Nishimura, R; Williams, PJ; Yoneda, T | 1 |
| Brankamp, J; Eberhardt, C; Kurth, AH; Schwarz, M; Stumpf, U | 1 |
| Russell, RG | 1 |
| Bauss, F; Dempster, DW | 1 |
| Athavale, S; Aya-ay, J; Bauss, F; Bian, H; Kim, HK; Morgan-Bagley, S | 1 |
| Bauss, F; Eberhardt, C; Habermann, B; Kurth, AH; Müller, S; Schwarz, M | 1 |
| Bauss, F; Hayes, WC; Kim, SZ; Kurth, AA; Müller, R; Shea, M | 1 |
| Skoglund, B | 1 |
| Bauss, F; Ghilardi, JR; Halvorson, KG; Koewler, NJ; Mantyh, PW; Sevcik, MA; Sullivan, LJ | 1 |
| Antic, VN; Fleisch, H; Mühlbauer, RC | 1 |
| Alsina, M; Anderson, JL; Craig, F; Cruz, JC; Dallas, M; Roodman, GD; Yoneda, T | 1 |
4 review(s) available for ibandronic acid and Disease Models, Animal
| Article | Year |
|---|---|
[Pharmacological profile and clinical evidence in patients with primary osteoporosis treated with intravenous ibandronate].
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Cholecalciferol; Diphosphonates; Disease Models, Animal; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Durapatite; Haplorhini; Humans; Ibandronic Acid; Infusions, Intravenous; Osteoporosis; Randomized Controlled Trials as Topic; Rats; Spinal Fractures | 2014 |
Novel therapeutic options for osteoporosis.
Topics: Animals; Controlled Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Evidence-Based Medicine; Fractures, Spontaneous; Glycoproteins; Humans; Ibandronic Acid; Imidazoles; Norpregnenes; Osteoporosis; Osteoprotegerin; Piperidines; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Selective Estrogen Receptor Modulators; Thiophenes; Zoledronic Acid | 2002 |
Ibandronate: pharmacology and preclinical studies.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Ibandronic Acid; Osteoporosis; Ovariectomy | 2006 |
Effects of ibandronate on bone quality: preclinical studies.
Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcification, Physiologic; Diphosphonates; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Haplorhini; Ibandronic Acid; Osteoporosis; Rats | 2007 |
12 other study(ies) available for ibandronic acid and Disease Models, Animal
| Article | Year |
|---|---|
Micro-CT imaging analysis for the effects of ibandronate and eldecalcitol on secondary osteoporosis and arthritis in adjuvant-induced arthritis rats.
Topics: Animals; Arthritis, Experimental; Biopsy; Disease Models, Animal; Ibandronic Acid; Imaging, Three-Dimensional; Joints; Osteoporosis; Phenotype; Proteoglycans; Rats; Vitamin D; X-Ray Microtomography | 2019 |
Local administration of ibandronate and bone morphogenetic protein-2 after ischemic osteonecrosis of the immature femoral head: a combined therapy that stimulates bone formation and decreases femoral head deformity.
Topics: Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Diphosphonates; Disease Models, Animal; Drug Therapy, Combination; Femur Head Necrosis; Ibandronic Acid; Male; Osteogenesis | 2011 |
Effect of dosing interval duration of intermittent ibandronate treatment on the healing process of femoral osteotomy in a rat fracture model.
Topics: Animals; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Femoral Fractures; Femur; Fracture Healing; Ibandronic Acid; Osteotomy; Radiography; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2012 |
The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs.
Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease Models, Animal; Doxorubicin; Female; Heart Neoplasms; Humans; Ibandronic Acid; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Tumor Cells, Cultured | 2002 |
Osseointegration of cementless implants with different bisphosphonate regimens.
Topics: Analysis of Variance; Animals; Biopsy, Needle; Bone Cements; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Femur; Ibandronic Acid; Immunohistochemistry; Injections, Intralesional; Osseointegration; Prostheses and Implants; Radiography; Random Allocation; Rats; Rats, Sprague-Dawley; Reference Values; Sensitivity and Specificity; Titanium | 2006 |
Retention, distribution, and effects of intraosseously administered ibandronate in the infarcted femoral head.
Topics: Animals; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Disease Models, Animal; Femur; Ibandronic Acid; Infarction; Swine | 2007 |
The bisphosphonate ibandronate accelerates osseointegration of hydroxyapatite-coated cementless implants in an animal model.
Topics: Animals; Bone Density Conservation Agents; Coated Materials, Biocompatible; Diphosphonates; Disease Models, Animal; Durapatite; Female; Femoral Fractures; Ibandronic Acid; Injections, Subcutaneous; Osseointegration; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2007 |
Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Carcinoma 256, Walker; Diphosphonates; Disease Models, Animal; Female; Femur; Ibandronic Acid; Image Processing, Computer-Assisted; Rats | 2007 |
Linköping University Medical Dissertation No. 1033. Following the mevalonate pathway to bone heal alley.
Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Density Conservation Agents; Coated Materials, Biocompatible; Diphosphonates; Disease Models, Animal; Femoral Fractures; Fracture Healing; Fractures, Bone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Injections, Subcutaneous; Male; Mevalonic Acid; Mice; Mice, Inbred BALB C; Rats; Rats, Sprague-Dawley; Simvastatin | 2007 |
Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer.
Topics: Animals; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Ibandronic Acid; Injections, Intravenous; Male; Mice; Mice, Inbred C3H; Osteolysis; Osteosarcoma; Pain; Pain Measurement; Treatment Outcome | 2008 |
Effect of bisphosphonates on the increase in bone resorption induced by a low calcium diet.
Topics: Alendronate; Animals; Bone Resorption; Calcium; Calcium, Dietary; Clodronic Acid; Diphosphonates; Disease Models, Animal; Homeostasis; Ibandronic Acid; Male; Rats; Rats, Wistar; Tetracycline | 1996 |
Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma.
Topics: Animals; Bone Diseases; Bone Marrow Cells; Cell Division; Cell Survival; Diphosphonates; Disease Models, Animal; Humans; Hypercalcemia; Ibandronic Acid; Immunoglobulin G; Immunoglobulin kappa-Chains; Leukemia, Plasma Cell; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Osteoclasts; Osteolysis; Paraplegia; Tumor Cells, Cultured | 2001 |